Platinum Chemotherapy After PARP Inhibition in HRR-Deficient Metastatic Castration-Resistant Prostate Cancer

IF 2.3 3区医学 Q3 ONCOLOGY

Clinical genitourinary cancer Pub Date : 2024-08-10 DOI:10.1016/j.clgc.2024.102187

Jennifer Obasi , Komal Sharma , Navonil De Sarkar , Emmanuel S. Antonarakis , Deepak Kilari

引用次数: 0

Abstract

•
PARP inhibitors can be efficacious in a selected cohort of prostate cancer patients with HRD.
•
A significant fraction of PARP inhibitor resistance occurs due to adoption of PARylation bypass mechanisms, while still maintaining HRRd status in the cancer cell.
•
In this subset of patients, Carboplatin can be considered for salvage if reversion mutations are not detected following PARP inhibitor failure.

查看原文本刊更多论文

PARP抑制后的铂化疗在HRR缺陷的转移性阉割耐药前列腺癌中的应用

-在这部分患者中，如果 PARP 抑制剂失效后未检测到逆转突变，可考虑使用卡铂进行挽救。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical genitourinary cancer 医学-泌尿学与肾脏学

CiteScore

5.20

自引率

6.20%

发文量

201

审稿时长

54 days

期刊介绍： Clinical Genitourinary Cancer is a peer-reviewed journal that publishes original articles describing various aspects of clinical and translational research in genitourinary cancers. Clinical Genitourinary Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of genitourinary cancers. The main emphasis is on recent scientific developments in all areas related to genitourinary malignancies. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.